Global Women's Health Therapeutics Market 2021

January 2022 | 22 pages | ID: GE040156DC90EN
StrategyHelix Inc

Abstracts

Women's health refers to the branch of medicine that focuses on the treatment and diagnosis of diseases and conditions that affect a woman's physical and emotional well-being. The global women's health therapeutics market is set to increase by US$ 15,079 million from 2021 to 2027, representing a compound annual growth rate (CAGR) of 5.1% during the forecast period.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for women's health therapeutics. The global women's health therapeutics market is segmented on the basis of disease, and region. On the basis of disease, the global women's health therapeutics market has been segmented into breast cancer, postmenopausal osteoporosis, menopause, endometriosis, polycystic ovary syndrome (PCOS). The breast cancer segment held the largest revenue share in 2020. In terms of geography, the global women's health therapeutics market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global women's health therapeutics market is highly competitive. Top players covered in Global Women's Health Therapeutics Market Study are AbbVie Inc., Amgen Inc., Asahi Kasei Corporation, AstraZeneca plc, Bayer AG, Bristol Myers Squibb (BMS), Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the women's health therapeutics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope
Disease: breast cancer, postmenopausal osteoporosis, menopause, endometriosis, polycystic ovary syndrome (PCOS)
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global women's health therapeutics market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. WOMEN'S HEALTH THERAPEUTICS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY DISEASE

Breast cancer
Postmenopausal osteoporosis
Menopause
Endometriosis
Polycystic ovary syndrome (PCOS)

PART 4. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 5. KEY COMPANIES

AbbVie Inc.
Amgen Inc.
Asahi Kasei Corporation
AstraZeneca plc
Bayer AG
Bristol Myers Squibb (BMS)
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
About StrategyHelix
Disclaimer